Table III.
Clinicopathological characteristics according to BCF group classificaction in the PSA nadir <0.008 ng/ml group.
| Characteristics | Total, no. (%) (n=183) |
BCF (−), no. (%) [n=173 (94.5)] |
BCF (+), no. (%) [n=10 (5.5)] |
|---|---|---|---|
| Median age, years (range) | 66 (47–77) | 66 (47–77) | 70 (63–73) |
| Median preoperative PSA, ng/ml (range) | 7.491 (0.959–39.413) | 7.491 (0.959–39.413) | 7.652 (5.024–15.403) |
| Clinical stage, n (%) | |||
| cT1c | 90 (49.2) | 87 (50.3) | 3 (30.0) |
| ≥cT2 | 93 (50.8) | 86 (49.7) | 7 (70.0) |
| Pathological stage, n (%) | |||
| ≤pT2 | 129 (70.5) | 125 (72.3) | 4 (40.0) |
| ≥pT3 | 54 (29.5) | 48 (27.7) | 6 (60.0) |
| RP Gleason score, n (%) | |||
| ≤7 | 141 (77.0) | 137 (79.2) | 4 (40.0) |
| ≥8 | 42 (33.0) | 36 (20.8) | 6 (60.0) |
| EPE, n (%) | |||
| 0 | 133 (72.7) | 129 (74.6) | 4 (40.0) |
| 1 | 50 (27.3) | 44 (25.4) | 6 (60.0) |
| RM, n (%) | |||
| 0 | 158 (86.3) | 150 (86.7) | 8 (80.0) |
| 1 | 25 (13.7) | 23 (13.3) | 2 (20.0) |
| pN, n (%) | |||
| 0 | 180 (98.4) | 172 (99.4) | 8 (80.0) |
| 1 | 3 (1.6) | 1 (0.6) | 2 (20.0) |
| PSA ≥0.008 ng/ml after PSA nadir, n (%) | 64 (35.0) | 54 (31.2) | 10 (100) |
BCF, biochemical failure: two consecutive values ≥0.2 ng/ml; PSA, prostate-specific antigen; RP, radical prostatectomy; EPE, extraprostatic extension; RM, resection margin.